ZYBERNO
Stock Report
Updated Sep 1, 2026

VivoSim Labs, Inc. (VIVS)

Healthcare • NASDAQ

$0.28

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
11.0/100
POOR BUSINESS
VivoSim Labs, Inc. (VIVS) scores 11/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-201.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-10,145.9%)
Return on Capital (Capital Efficiency):CRITICAL (-381.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VivoSim Labs, Inc. (VIVS) stock report — Zyberno Score 11/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.28
Market Cap:$1.46M

Valuation Multiples (2)

P/S Ratio:13.40x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$422.24K

Price Action & Momentum (1)

% of 52-Week High:5.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-116.0%
Reinvestment Rate:2.6%
Fundamental Growth Rate (g):-9.9%

Margin Analysis (3)

Operating Margin Ttm:-10,145.9%
Net Margin Ttm:-8,639.4%
Ebitda Margin:-9,951.4%

TTM Performance (3)

Gross Margin Ttm:127.5%
Operating Margin Ttm:-10,145.9%
Net Margin Ttm:-8,639.4%

Yield Metrics (2)

Earnings Yield:-$1.05K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:80.3%
Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-41.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.70x
Quick Ratio:1.70x
Cash Ratio:0.88x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-957.25x
Times Interest Earned:-957.25

Capital Structure (4)

Working Capital:1,333,000.00
Cash And Cash Equivalents:1,670,000.00
Long Term Debt:$316.00K
Net Debt:-$1.04M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $109.00K
Linear Growth: -41.0%
📊 Click to view full VIVS Revenue analysis & methodology →
Cost Of Revenue Ttm:$5.00K

Profitability Breakdown (2)

Gross profit TTM: $139.00K
Linear Growth: -36.3%
📊 Click to view full VIVS Gross Profit analysis & methodology →
-$11.06M

Bottom Line Performance (3)

-$9.42M
Income Before Tax:-$13.84M
Ebitda Ttm:-10,847,000.00

Operating Expenses (5)

Operating Expenses:11,168,000.00
R And D Expense:4,196,000.00
Sga Expense:6,972,000.00
Income Tax Expense:$5.00K
Interest Expense:12,000.00

Expense Ratios (3)

R And D To Revenue Percentage:23,311.1%
Sga To Revenue Percentage:38,733.3%
Ebitda Margin:-9,951.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.85M
Current Assets:$3.23M
Ppe Net:189,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:6,193,000.00
Current Liabilities:1,893,000.00
Long Term Debt:$316.00K
Short Term Debt:$316.00K

Equity & Capital (3)

Equity:-$2.35M
Retained Earnings:-$357.34M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:29,000.00
Inventory:0.00
Accounts Payable:621,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:91,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$11.80M-$10.83M

Investment Activities (1)

Investing Cash Flow:-$23.00K

Financing Activities (3)

Financing Cash Flow:-$118.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:212,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.40
-$3.40
Earnings Per Share Ttm:-$1.80

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.02
Operating Cash Flow Per Share:-$2.07

Book Value & Capital (2)

Book Value Per Share:-$0.45
Cash Per Share:0.32

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.08x

Receivables Management (2)

Receivables Turnover Ttm:3.76x
Days Sales Outstanding Ttm:97.11

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:45,333.00
Cash Conversion Cycle:-46,234.89
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.6%
Fundamental Growth Rate (g):-9.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-41.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-36.3%
Book Value Growth Rate (Linear):-24.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:VIVS
Company Name:VivoSim Labs, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.24M
Shares Outstanding Basic:5.24M
Shares Outstanding Diluted:5.24M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 20:09:12 UTC
Data Timestamp:2026-08-22T09:07:41.668967
Scroll to Top